Representative Jared Moskowitz (D-Florida) recently sold shares of West Pharmaceutical Services, Inc. NYSE: WST. In a filing disclosed on March 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in West Pharmaceutical Services stock on February 13th. The trade occurred in the Representative's "MORGAN STANLEY ACTIVE ASSETS (6)" account.
Representative Jared Moskowitz also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 1/15/2025.
- Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 1/15/2025.
- Sold $1,001 - $15,000 in shares of Canadian National Railway NYSE: CNI on 1/15/2025.
- Purchased $1,001 - $15,000 in shares of Stryker NYSE: SYK on 1/15/2025.
- Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 1/15/2025.
- Sold $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 1/15/2025.
- Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 1/15/2025.
West Pharmaceutical Services Price Performance
WST stock traded up $5.72 during mid-day trading on Tuesday, reaching $231.76. The company's stock had a trading volume of 1,264,901 shares, compared to its average volume of 983,277. The stock has a market cap of $16.76 billion, a PE ratio of 34.64, a P/E/G ratio of 6.74 and a beta of 1.09. The company has a current ratio of 2.79, a quick ratio of 2.23 and a debt-to-equity ratio of 0.08. West Pharmaceutical Services, Inc. has a fifty-two week low of $197.01 and a fifty-two week high of $400.88. The company's 50 day moving average is $293.33 and its two-hundred day moving average is $305.33.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.07. The company had revenue of $748.80 million during the quarter, compared to the consensus estimate of $739.59 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. Equities research analysts expect that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.
West Pharmaceutical Services Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 7th. Investors of record on Wednesday, April 30th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.36%. The ex-dividend date of this dividend is Wednesday, April 30th. West Pharmaceutical Services's dividend payout ratio is presently 12.56%.
Hedge Funds Weigh In On West Pharmaceutical Services
Several large investors have recently bought and sold shares of WST. Quadrant Capital Group LLC raised its holdings in shares of West Pharmaceutical Services by 5.4% in the fourth quarter. Quadrant Capital Group LLC now owns 626 shares of the medical instruments supplier's stock valued at $205,000 after buying an additional 32 shares during the last quarter. Baron Wealth Management LLC raised its holdings in West Pharmaceutical Services by 1.9% during the fourth quarter. Baron Wealth Management LLC now owns 1,926 shares of the medical instruments supplier's stock worth $631,000 after purchasing an additional 35 shares in the last quarter. Exchange Traded Concepts LLC grew its position in West Pharmaceutical Services by 18.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier's stock worth $78,000 after buying an additional 38 shares during the period. Lake Street Advisors Group LLC grew its position in West Pharmaceutical Services by 5.8% during the fourth quarter. Lake Street Advisors Group LLC now owns 711 shares of the medical instruments supplier's stock worth $233,000 after buying an additional 39 shares during the period. Finally, Covestor Ltd grew its position in West Pharmaceutical Services by 14.3% during the third quarter. Covestor Ltd now owns 320 shares of the medical instruments supplier's stock worth $96,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 93.90% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on WST. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 price target for the company in a report on Friday, February 14th. KeyCorp cut their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. StockNews.com downgraded shares of West Pharmaceutical Services from a "buy" rating to a "hold" rating in a research note on Thursday, February 27th. Bank of America boosted their target price on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Finally, UBS Group upgraded shares of West Pharmaceutical Services from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $350.00 to $390.00 in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $344.00.
Check Out Our Latest Analysis on West Pharmaceutical Services
About Representative Moskowitz
Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida's 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida's 23rd Congressional District. He declared candidacy for the 2026 election.
Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor's degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz's career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.
West Pharmaceutical Services Company Profile
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
